Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Stryker Corp Stock Research

SYK

293.71USD+0.49(+0.17%)Market Closed
Watchlist

Market Summary

USD293.71+0.49
Market Closed
0.17%

SYK Alerts

  • 1 major insider sales recently.

SYK Stock Price

SYK RSI Chart

SYK Valuation

Market Cap

111.5B

Price/Earnings (Trailing)

41.17

Price/Sales (Trailing)

5.73

EV/EBITDA

31.15

Price/Free Cashflow

46.14

SYK Price/Sales (Trailing)

SYK Profitability

Operating Margin

62.58%

EBT Margin

15.70%

Return on Equity

15.55%

Return on Assets

7.13%

Free Cashflow Yield

2.17%

SYK Fundamentals

SYK Revenue

Revenue (TTM)

19.5B

Revenue Y/Y

11.2%

Revenue Q/Q

4.56%

SYK Earnings

Earnings (TTM)

2.7B

Earnings Y/Y

12.5%

Earnings Q/Q

24.66%

Price Action

52 Week Range

200.12306.93
(Low)(High)

Last 7 days

-0.4%

Last 30 days

5.7%

Last 90 days

-1.3%

Trailing 12 Months

33.0%

SYK Financial Health

Current Ratio

1.73

SYK Investor Care

Dividend Yield

1%

Dividend/Share (TTM)

2.93

Shares Dilution (1Y)

0.37%

Diluted EPS (TTM)

7.08

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for SYK

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-06
Menon Viju
sold
-1,445,000
289
-5,000
group president
2023-08-10
Datar Srikant M.
sold
-214,671
286
-750
-
2023-08-08
Datar Srikant M.
acquired
186,120
93.06
2,000
-
2023-08-08
Datar Srikant M.
sold (taxes)
-186,362
286
-651
-
2023-08-01
Fletcher Robert S
sold (taxes)
-95,792
283
-338
vp, chief legal officer
2023-06-09
Lobo Kevin
gifted
-
-
-8,904
chair and ceo
2023-06-05
Lobo Kevin
gifted
-
-
-8,904
chair and ceo
2023-06-01
Datar Srikant M.
sold
-139,250
278
-500
-
2023-05-18
Datar Srikant M.
sold
-286,000
286
-1,000
-
2023-05-10
Skeete Tatum Lisa M
acquired
-
-
705
-

1–10 of 50

Which funds bought or sold SYK recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-15
CJM Wealth Advisers, Ltd.
unchanged
-
15,892
247,123
0.12%
2023-09-12
Farther Finance Advisors, LLC
added
55.67
128,646
322,480
0.07%
2023-09-11
Dechtman Wealth Management, LLC
new
-
360,980
360,980
0.11%
2023-09-08
TUCKER ASSET MANAGEMENT LLC
unchanged
-
1,196
18,610
-%
2023-09-07
ST GERMAIN D J CO INC
new
-
590,349
590,349
0.03%
2023-09-05
Delos Wealth Advisors, LLC
unchanged
-
20.00
306
-%
2023-09-05
Covenant Partners, LLC
added
4.06
48,856
484,483
0.17%
2023-09-01
Manhattan West Asset Management, LLC
reduced
-15.81
-32,401
290,751
0.11%
2023-08-30
Western Wealth Management, LLC
added
1.46
32,986
424,097
0.04%
2023-08-29
EFG Asset Management (Americas) Corp.
reduced
-3.8
11,425
417,363
0.10%

1–10 of 48

Latest Funds Activity

Are funds buying SYK calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SYK
No. of Funds

Schedule 13G FIlings of Stryker

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
price t rowe associates inc /md/
4.0%
14,929,245
SC 13G/A
Feb 10, 2023
greenleaf trust
5.3%
19,869,434
SC 13G/A
Feb 09, 2023
vanguard group inc
7.99%
30,246,178
SC 13G/A
Feb 01, 2023
blackrock inc.
6.5%
24,494,206
SC 13G/A
Feb 14, 2022
price t rowe associates inc /md/
5.5%
21,156,776
SC 13G/A
Feb 11, 2022
greenleaf trust
5.4%
20,452,972
SC 13G/A
Feb 10, 2022
vanguard group inc
7.60%
28,652,681
SC 13G/A
Feb 07, 2022
blackrock inc.
6.3%
23,860,749
SC 13G/A
Feb 16, 2021
price t rowe associates inc /md/
7.9%
29,889,060
SC 13G/A
Feb 11, 2021
greenleaf trust
5.6%
21,048,539
SC 13G/A

Recent SEC filings of Stryker

View All Filings
Date Filed Form Type Document
Sep 08, 2023
4
Insider Trading
Sep 06, 2023
144
Notice of Insider Sale Intent
Aug 10, 2023
4
Insider Trading
Aug 08, 2023
144
Notice of Insider Sale Intent
Aug 04, 2023
10-Q
Quarterly Report
Aug 03, 2023
8-K
Current Report
Aug 03, 2023
4
Insider Trading
Jun 16, 2023
8-K
Current Report
Jun 15, 2023
4/A
Insider Trading
Jun 13, 2023
4
Insider Trading

Peers (Alternatives to Stryker)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
111.5B
19.5B
5.69% 32.97%
41.17
5.73
10.36% 30.30%
105.3B
6.7B
4.79% 48.19%
73.87
15.8
11.75% -0.66%
76.7B
13.4B
5.66% 28.78%
84.09
5.72
8.69% 3.17%
71.3B
19.0B
-2.82% 6.66%
44.09
3.79
0.46% -5.24%
44.4B
5.7B
-4.65% -17.80%
31.95
7.85
5.64% -4.53%
MID-CAP
10.1B
937.8M
4.57% 35.10%
345.61
10.73
16.30% 250.21%
7.7B
616.6M
-5.28% -28.68%
31.46
12.45
69.52% 343.68%
5.3B
1.1B
-3.27% -11.90%
25.4
4.87
12.63% 50.85%
2.9B
452.1M
-15.03% -38.95%
-28.79
6.32
24.99% 24.09%
1.4B
790.3M
-24.48% -59.71%
-6.39
1.81
3.21% -1604.53%
SMALL-CAP
1.6B
421.8M
-7.15% 55.58%
-9.77
3.87
44.49% -2.43%
959.6M
780.7M
-7.16% -11.41%
-26.66
1.23
4.68% -510.17%
839.3M
239.8M
0.70% 0.15%
-22.16
3.5
-4.74% -31.15%
637.3M
162.9M
-22.73% -61.80%
-12.05
3.91
42.67% 12.82%

Stryker News

MarketBeat
Transcend Capital Advisors LLC Raises Stock Position in Stryker Co ....
MarketBeat,
51 minutes ago
Marketscreener.com
Yahoo Finance
Zacks Investment Research
InvestorsObserver

Returns for SYK

Cumulative Returns on SYK

16.5%


10-Year Cumulative Returns

15.5%


7-Year Cumulative Returns

12.1%


5-Year Cumulative Returns

13.3%


3-Year Cumulative Returns

Risks for SYK

What is the probability of a big loss on SYK?

36.9%


Probability that Stryker stock will be more than 20% underwater in next one year

18.5%


Probability that Stryker stock will be more than 30% underwater in next one year.

0%


Probability that Stryker stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does SYK drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Stryker was unfortunately bought at previous high price.

Drawdowns

Financials for Stryker

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue2.7%19,45518,95218,44917,94817,62917,43017,10816,66916,24614,71614,35114,22014,07014,95614,88414,54914,20413,87613,60113,27613,040
Gross Profit3.0%12,21511,86011,57811,38711,24711,19310,96810,64010,4599,2359,0579,0438,9129,7449,6969,4499,2749,0848,9388,7238,552
Operating Expenses1.9%8,8938,7318,7378,5418,6358,6218,3848,1267,6607,1886,8346,6256,7256,9246,9836,9826,8596,6106,4016,1706,050
  S&GA Expenses2.6%6,6936,5266,4556,4496,5966,5626,4276,2445,8865,6065,3615,1795,2265,2835,3565,4075,3585,2665,0994,8854,746
  R&D Expenses-0.4%1,3751,3801,4541,4591,4011,3601,2351,1591,0951,0189849839871,000971938913883862846823
EBITDA-100.0%-3,6753,378-2,7272,9932,977--2,5462,7693,0162,8173,4693,3593,0422,9953,0533,1153,0903,027
EBITDA Margin-100.0%-0.19*0.18*-0.15*0.17*0.17*--0.17*0.19*0.21*0.20*0.23*0.23*0.21*0.21*0.22*0.23*0.23*0.23*
Interest Expenses---324---325---304---286---248--
Earnings Before Taxes6.0%3,1552,9762,6832,6792,3582,3002,2812,1952,4801,7311,9542,2192,0202,6722,5622,2832,2362,2942,3562,3482,285
EBT Margin-100.0%-0.16*0.15*0.15*0.13*0.13*0.13*0.13*0.15*0.12*0.14*0.16*0.14*0.18*0.17*0.16*0.16*0.17*0.17*0.18*0.18*
Net Income3.1%2,7092,6272,3582,4572,0792,0151,9941,9002,0831,4081,5991,7561,6012,1642,0833,4263,5503,5223,5531,2361,080
Net Income Margin-100.0%-0.14*0.13*0.14*0.12*0.12*0.12*0.11*0.13*0.10*0.11*0.12*0.11*0.14*0.14*0.24*0.25*0.25*0.26*0.09*0.08*
Free Cashflow-100.0%-2,2672,0362,0152,0672,4532,7383,0162,9732,7122,7902,2541,9601,7981,5421,8981,9102,0532,0381,6391,098
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets1.6%37,40936,83036,88435,98336,03236,13734,63134,14533,69833,45534,33032,28631,48329,44030,16726,65926,35425,93727,22922,08421,570
  Current Assets0.0%10,15110,15510,2759,3188,8258,72510,0179,4609,0328,9799,70713,54512,80110,73611,0588,5668,1857,8889,7337,9187,413
    Cash Equivalents-16.2%1,4011,6711,8441,4201,0441,4582,9442,5632,2412,2382,9437,0836,5393,9644,3371,9481,7541,6743,6161,9181,641
  Inventory6.0%4,5934,3333,9953,8833,7493,5253,3143,4343,4313,4733,4943,4593,4423,3592,9803,2693,1983,0642,9552,8932,740
  Net PPE1.5%3,0823,0372,9702,7982,8032,7932,8332,7462,7382,7102,7522,5292,5272,6072,5672,4602,3872,2972,2912,1782,101
  Goodwill2.2%15,17214,84914,88014,99315,11515,22812,91812,89312,80212,80312,7789,1289,0749,0259,0698,7048,7621148,5637,6347,636
Liabilities0.6%20,04819,93520,26819,52020,35821,09119,75419,96719,87819,95321,24619,30018,72916,32517,36014,34414,41114,24415,49912,22412,110
  Current Liabilities12.2%6,5845,8666,3034,5714,4044,4084,5494,4494,2523,9535,0414,6894,4054,1624,4003,9213,9463,7134,8074,1534,046
    LT Debt, Non Current-6.0%11,14911,85711,85712,75113,37413,88512,47212,62912,73413,05913,23012,00811,8119,40410,2317,8897,9747,9508,4865,9285,925
Shareholder's Equity2.8%17,36116,89516,61616,46315,67415,04614,87714,17813,82013,50213,08412,98612,75413,11512,80712,31511,94311,69311,7309,8609,460
  Retained Earnings3.0%15,52615,07214,76514,48613,93313,54013,48013,08112,88112,52512,46212,12911,72512,02411,74811,23810,96710,68310,7658,8928,477
  Additional Paid-In Capital1.8%2,1272,0902,0342,0281,9891,9471,8901,8751,8441,8061,7411,7361,7061,6761,6281,5931,5691,5381,5591,5351,503
Accumulated Depreciation2.5%3,0052,9332,8352,7362,7462,7392,6652,6942,6242,4962,4302,3102,2482,1692,1472,1432,0912,0451,9861,9741,935
Shares Outstanding0.2%380379-378378378-377377376-376376375-374374373-374374
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations5.5%3,0252,8662,6242,6212,6653,0143,2633,5003,3963,1383,2772,7752,5752,4692,1912,5022,4912,6262,6102,2431,704
  Share Based Compensation1.8%174171168170171174171168163154142147150148127127125125119115112
Cashflow From Investing-101.9%-755-374-2,924-3,076-3,395-3,445-859-4,897-4,719-4,634-4,701-1,068-1,185-1,315-1,455-2,364-2,334-2,311-2,857-1,689-2,348
Cashflow From Financing15.7%-1,875-2,223-749-591-396-319-2,365-3,134-3,028-296-11.003,4093,4261,1823.00-80.00-34.00-7631,329-1,223-1,389
  Dividend Payments2.1%1,0951,0731,0511,0251,000974950929907886863840819798778760741722703687670
  Buy Backs---------------307307307307300300300

SYK Income Statement

2023-06-30
CONSOLIDATED STATEMENTS OF EARNINGS (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
Net sales$ 4,996$ 4,493$ 9,774$ 8,768
Cost of sales1,8151,6673,5773,208
Gross profit3,1812,8266,1975,560
Research, development and engineering expenses346351685764
Selling, general and administrative expenses1,7061,5393,4873,249
Recall charges, net34318
Amortization of intangible assets161160322310
Total operating expenses2,2162,0544,4974,341
Operating income9657721,7001,219
Other income (expense), net(66)(52)(122)(113)
Earnings before income taxes8997201,5781,106
Income taxes16164248127
Net earnings$ 738$ 656$ 1,330$ 979
Net earnings per share of common stock:    
Basic (in dollars per share)$ 1.95$ 1.73$ 3.51$ 2.59
Diluted (in dollars per share)$ 1.93$ 1.72$ 3.47$ 2.56
Weighted-average shares outstanding (in millions):    
Basic (in shares)379.7378.3379.4378.0
Effect of dilutive employee stock compensation (in shares)4.23.94.24.5
Diluted (in shares)383.9382.2383.6382.5
Cash dividends declared per share of common stock (in dollars per share)$ 0.75$ 0.695$ 1.50$ 1.39

SYK Balance Sheet

2023-06-30
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 1,401$ 1,844
Marketable securities7784
Accounts receivable, less allowance of $181 ($154 in 2022)3,2613,565
Inventories:  
Materials and supplies1,2211,006
Work in process391348
Finished goods2,9812,641
Total inventories4,5933,995
Prepaid expenses and other current assets819787
Total current assets10,15110,275
Property, plant and equipment:  
Land, buildings and improvements1,6461,739
Machinery and equipment4,4414,066
Total property, plant and equipment6,0875,805
Less allowance for depreciation3,0052,835
Property, plant and equipment, net3,0822,970
Goodwill15,17214,880
Other intangibles, net4,9174,885
Noncurrent deferred income tax assets1,4391,410
Other noncurrent assets2,6482,464
Total assets37,40936,884
Current liabilities  
Accounts payable1,3261,413
Accrued compensation9291,149
Income taxes298292
Dividends payable284284
Accrued product liabilities220230
Accrued expenses and other liabilities1,7291,744
Current maturities of debt1,7981,191
Total current liabilities6,5846,303
Long-term debt, excluding current maturities11,14911,857
Income taxes469641
Other noncurrent liabilities1,8461,467
Total liabilities20,04820,268
Shareholders' equity  
Common stock, $0.10 par value3838
Additional paid-in capital2,1272,034
Retained earnings15,52614,765
Accumulated other comprehensive loss(330)(221)
Total shareholders' equity17,36116,616
Total liabilities and shareholders' equity$ 37,409$ 36,884
Kevin A. Lobo
46000
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.